Cell Therapy Clinical Trials for AutoImmune Diagnoses 2011-2015

PGCBWe are collaborating on a project to compile all cell therapy clinical trials registered worldwide from 2011 through 2015. Our database includes 58 clinical trials for autoimmune diseases, with a total planned enrollment of 2192 patients.

In this article we have prepared two figures to illustrate the importance of cell therapy clinical trials for autoimmune diseases and the variety of cell types currently in clinical trials for these diagnoses.

obzor_1

Figure 1: In this pie chart, the width of the pie slices is the number of patients that the clinical trials aim to enroll, and slices are color-coded by autoimmune diagnosis. The most common diagnosis is Multiple Sclerosis at 40% of patient enrollment.

obzor_2

Figure 2: In this bar graph, the height of each bar is the number of patients that the clinical trials aim to enroll. There are separate bars for various types of cell sources, and within each bar they are color-coded by whether the source is autologous or allogeneic. In this graph 1256 (57%) patients are receiving autologous cell therapy and 1351 (62%) patients are receiving MSC therapy.

Alexey Bersenev, MD PhD, Pedro Silva Couto, MSc, Frances Verter PhD
Source: http://parentsguidecordblood.org/

Among Ukraine’s medical institutions Institute of Cell Therapy was the first to receive in 2008 permission of Coordination Center of Transplantation of the Ministry of Health of Ukraine to conduct clinical trials using stem cells. After 5-year clinical trials treatments for chronic lower limb ischemia and pancreatic necrosis with the use of umbilical cord blood stem cells, developed by the Institute of Cell Therapy, in 2012 got official approval of the Ministry of Health of Ukraine. Currently the Institute of Cell Therapy continues clinical trials of cell therapies of cardiomyopathy, liver cirrhosis and viral hepatitis, as well as type 2 diabetes mellitus.

No Comments Yet.

Leave a comment

You must be logged in to post a comment.